- Home
- CHRS vs MRCC Comparison
CHRS vs MRCC Comparison
Compare CHRS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MRCC
- Stock Information
- Founded
- CHRS 2010
- MRCC 2011
- Country
- CHRS United States
- MRCC United States
- Employees
- CHRS N/A
- MRCC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MRCC Investment Managers
- Sector
- CHRS Health Care
- MRCC Finance
- Exchange
- CHRS Nasdaq
- MRCC Nasdaq
- Market Cap
- CHRS 191.3M
- MRCC 174.8M
- IPO Year
- CHRS 2014
- MRCC 2012
- Fundamental
- Price
- CHRS $1.24
- MRCC $8.46
- Analyst Decision
- CHRS Strong Buy
- MRCC Strong Buy
- Analyst Count
- CHRS 4
- MRCC 1
- Target Price
- CHRS $5.38
- MRCC $9.00
- AVG Volume (30 Days)
- CHRS 2.0M
- MRCC 64.1K
- Earning Date
- CHRS 03-12-2025
- MRCC 03-10-2025
- Dividend Yield
- CHRS N/A
- MRCC 11.68%
- EPS Growth
- CHRS N/A
- MRCC 298.01
- EPS
- CHRS N/A
- MRCC 0.60
- Revenue
- CHRS $304,340,000.00
- MRCC $62,007,000.00
- Revenue This Year
- CHRS $2.47
- MRCC N/A
- Revenue Next Year
- CHRS N/A
- MRCC N/A
- P/E Ratio
- CHRS N/A
- MRCC $14.27
- Revenue Growth
- CHRS 44.19
- MRCC N/A
- 52 Week Low
- CHRS $0.66
- MRCC $6.97
- 52 Week High
- CHRS $2.87
- MRCC $8.80
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- MRCC 52.90
- Support Level
- CHRS $1.38
- MRCC $8.30
- Resistance Level
- CHRS $1.45
- MRCC $8.79
- Average True Range (ATR)
- CHRS 0.13
- MRCC 0.19
- MACD
- CHRS -0.04
- MRCC 0.02
- Stochastic Oscillator
- CHRS 4.50
- MRCC 52.17
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.